[Barrier drugs with prolonged release in dental practice]

Area of Science:

• Dentistry
• Pharmaceutical Sciences
• Biomaterials

Background:

• Pathological lesions of the oral mucosa are common in dental practice, stemming from diverse causes like infections and physical agents.
• Traditional topical treatments (ointments, gels) exhibit limited efficacy due to poor drug concentration maintenance, short contact times, and patient discomfort.
• These limitations necessitate the development of advanced pharmaceutical forms for improved oral lesion management.

Purpose of the Study:

• To address the limitations of conventional topical therapies for oral mucosal lesions.
• To explore the development of novel pharmaceutical forms with enhanced adhesion and prolonged drug release.
• To improve the therapeutic outcomes and patient experience in managing oral mucosal pathologies.

Main Methods:

• Development of novel pharmaceutical formulations designed for prolonged activity and improved mucosal adhesion.
• Evaluation of drug concentration maintenance and contact duration at the lesion site.
• Assessment of protective properties against infection and external irritants.
• Clinical evaluation of pain reduction during mastication and mimicry.

Main Results:

• New barrier drugs and prolonged-release formulations demonstrate improved adhesion to oral mucosa.
• These advanced forms maintain therapeutic drug concentrations for extended periods.
• Enhanced protection against oral infections and external influences, with reduced pain during oral functions.

Conclusions:

• Advanced pharmaceutical forms, including barrier and prolonged-release drugs, offer significant advantages over traditional topical treatments for oral mucosal lesions.
• These novel formulations improve therapeutic efficacy, patient comfort, and treatment duration.
• Ongoing research and development continue to refine these pharmaceutical strategies for broader clinical application.